Mostrar el registro sencillo del ítem
Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MBWE MPOH, Maurice | |
| dc.contributor.author | DELI, Vandi | |
| dc.contributor.author | DANIEL, Tollo Tollo | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco
IDREF: 221043470 | |
| dc.date.accessioned | 2023-11-07T14:23:59Z | |
| dc.date.available | 2023-11-07T14:23:59Z | |
| dc.date.issued | 2023-06-15 | |
| dc.identifier.issn | 2212-554X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/184666 | |
| dc.description.abstractEn | Recognized in 1994 as a global emergency by the World Health Organization, tuberculosis (TB) remains an ongoing health threat. In Cameroon, the mortality rate is estimated at 2.9%. Treatment of multidrug-resistant TB (MDR-TB) defined as the resistance to the two most effective antiTB drugs, and requires therapy of more than 7 drugs taken on a daily basis during 9-12 months. This study aimed to evaluate the safety profile of treatment regimens used for MDR-TB at Jamot Hospital of Yaounde (JHY). This was a retrospective cohort study of patients treated for MDR-TB at HJY from January 1, 2017, to December 31, 2019. Patients characteristics of the cohort, drugs regimen were collected and described. All possible adverse drug reactions (ADR) were described clinically and by severity grade. During the study period, 107 patients were included, and 96 (89.7%) experienced at least one ADR. Most parts of the patients (90) experienced mild or moderate ADR. Hearing loss was the most frequent ADR, and led mostly in aminoglycosides dose reduction (n = 30, 96.7%). Gastrointestinal events were commonly observed during the study period. Our findings suggested that ototoxicity was a prominent safety issue during the study period. The implementation of the new short treatment regimen could be effective in reducing the burden of ototoxicity among MDR-TB patients. Nevertheless, new safety issues could emerge. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-ShareAlike 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/us/ | * |
| dc.subject.en | Humans | |
| dc.subject.en | Antitubercular Agents | |
| dc.subject.en | Cameroon | |
| dc.subject.en | Ototoxicity | |
| dc.subject.en | Retrospective Studies | |
| dc.subject.en | Tuberculosis | |
| dc.subject.en | Multidrug-Resistant | |
| dc.subject.en | Male | |
| dc.subject.en | Female | |
| dc.subject.en | Adult | |
| dc.subject.en | Middle Aged | |
| dc.subject.en | Cohort Studies | |
| dc.subject.en | Hearing Loss | |
| dc.subject.en | Time Factors | |
| dc.title.en | Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon | |
| dc.title.alternative | Int J Mycobacteriol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.4103/ijmy.ijmy_88_23 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 37338479 | en_US |
| dc.description.sponsorshipEurope | European programme in Pharmacovigilance and Pharmacoepidemiology | en_US |
| bordeaux.journal | International Journal of Mycobacteriology | en_US |
| bordeaux.page | 168-174 | en_US |
| bordeaux.volume | 12 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04273841 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-11-07T14:24:01Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Mycobacteriology&rft.date=2023-06-15&rft.volume=12&rft.issue=2&rft.spage=168-174&rft.epage=168-174&rft.eissn=2212-554X&rft.issn=2212-554X&rft.au=MBWE%20MPOH,%20Maurice&DELI,%20Vandi&DANIEL,%20Tollo%20Tollo&SALVO,%20Francesco&rft.genre=article |
